Kodiak Sciences Q3 net loss $43.9M, cash $197.9M; provides pipeline updates

Kodiak Sciences Inc.

2024-Q3 EPS reported -$2.51

Net loss of $43.9M ($0.84/sh) vs $50.0M ($0.95/sh) in Q3 2023; cash $197.9M expected to fund operations into 2026.
Phase 3 GLOW2 (diabetic retinopathy) and DAYBREAK (wet AMD) enrolling; enrollment completion targeted H1 2025.
KSI-101 APEX study enrolling; dose selection for pivotal studies expected Q2 2025.
Tarcocimab ocular half-life 20 days (3x faricimab, 2-3x aflibercept) presented at Sept R&D Day.
Preclinical ABCD pipeline expanded to glaucoma and geographic atrophy programs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.